Commodity Chemicals

NOF Corporation

NOF Corporation Reports Strong Fiscal Year Performance

Five Companies Form LNP Alliance to Advance Drug Development

4403

NOF Corporation (TSE:4403) has announced a share buyback program to repurchase up to 2 million shares, aiming to enhance shareholder returns. The company's share price has risen 28% year-to-date, with a P/E ratio of 18.7x, higher than industry averages, indicating potential overvaluation. A discounted cash flow analysis suggests shares are trading above fair value, raising concerns about growth expectations. Investors are encouraged to explore further investment opportunities while considering the risks associated with NOF's elevated valuation.

Simplywall

A Look at NOF Corporation's (TSE:4403) Valuation Following New Share Buyback Plan and Board Updates

The Board of Directors of NOF Corporation has authorized a buyback plan on November 6, 2025.

marketscreener

NOF Corporation authorizes a Buyback Plan.

NOF Corporation (TSE:4403) announces a share repurchase program. Under the program, the company will repurchase up to 2,000,000 shares, representing 0.87% of its total shares outstanding excluding treasury shares, for a total of ¥5,000 million. The purpose of repurchase program is to further return profits to shareholders with Mid-Term Management Plan.The repurchase program is valid till December 31, 2025. As of October 31, 2025, the company had 229,944,904 shares outstanding excluding treasury shares and had 6,579,224 shares in treasury.

NOF Corporation announces an Equity Buyback for 2,000,000 shares, representing 0.87% for ¥5,000 million.

NOF Corporation (TSE:4403) is set to trade ex-dividend in three days, with a dividend payment of JP¥24.00 per share on December 2nd. The company has a trailing yield of 1.8% based on a share price of JP¥2633.00. NOF paid out 31% of its profit last year and 76% of its free cash flow, indicating a sustainable dividend. Earnings per share have grown 12% annually over the last five years, and dividends have increased by an average of 17% per year over the past decade. Overall, NOF appears solid for dividend investors.

NOF Corporation (TSE:4403) Looks Interesting, And It's About To Pay A Dividend

NOF Corporation (TSE:4403) has seen its share price decline by 10% in the last month, but its five-year total shareholder return (TSR) stands at 109%, surpassing its share price return of 92%. The company's earnings per share (EPS) grew at an annual rate of 13%, closely aligning with the 14% increase in share price. Over the past year, shareholders enjoyed a 25% TSR, indicating positive sentiment. Despite recent price drops, the stock's long-term performance suggests potential for investors to consider.

NOF's (TSE:4403) five-year total shareholder returns outpace the underlying earnings growth

NOF Corporation reported strong fiscal year performance with a 7.2% increase in net sales to 238,310 million yen for the year ending March 31, 2025. Operating profit rose by 7.5%, while profit attributable to owners increased by 7.4%. The Functional Chemicals segment thrived due to high demand, although the Pharmaceuticals segment faced declines. The Explosives & Propulsion segment saw growth. Looking ahead, NOF expects continued growth and plans to expand its market presence despite global economic uncertainties.

Tip Ranks

Phosphorex, NOF CORPORATION, NeoSome Life Sciences, NanoImaging Services, and Envol Biomedical have formed the LNP Alliance to advance lipid nanoparticle (LNP) technology and expedite drug development. This collaboration combines expertise in lipid innovations, formulation, and analytical services to support biopharma companies. The alliance aims to provide comprehensive solutions from lipid synthesis to clinical success, enhancing the development of effective therapies. Key offerings include access to proprietary lipids, expert formulation, and extensive evaluation capabilities, underscoring a commitment to innovation in LNP-based therapeutics.

prnewswire

Nano-X Imaging

09:28 ET
			
			
				Phosphorex, NOF CORPORATION, NeoSome Life Sciences, NanoImaging Services, and Envol Biomedical Unite to Form the LNP Alliance--Accelerating Lipid Nanoparticle Drug Development